

## Special Issue

# Vaccines against SARS-CoV-2 Variants

### Message from the Guest Editor

During the two-year SARS-CoV-2 epidemic, several variants of concern (VOC) have evolved. The effectiveness of the COVID-19 vaccines declined significantly against VOCs. Additionally, vaccine-induced protection was reported to wane with time. Thus, vaccines that could protect people against SARS-CoV-2 variants and potential newly emerged coronaviruses are urgently needed. As such, the following questions have arisen: are there any potential techniques to be used for developing such kind of vaccines? What is the key to developing a vaccine against variants? What are the difficulties of the technique? How can we assess the effectiveness? What is the prospect of a universal coronavirus vaccine? What is the development status of universal vaccines against other pathogens? This Special issue will provide a platform for scholars to communicate their professional views and study results to boost universal coronavirus vaccines development.

---

### Guest Editor

Dr. Dingmei Zhang

Department of Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou 510080, China

---

### Deadline for manuscript submissions

closed (1 July 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/116888](https://mdpi.com/si/116888)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).